Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders.

ABSTRACT:

Background

Lubiprostone is a ClC-2 chloride channel activator approved for the treatment of chronic idiopathic constipation (CIC) and opioid-induced constipation (OIC) in adults and irritable bowel syndrome with constipation (IBS-C) in women. Lubiprostone is generally well tolerated, with nausea being the most common adverse event.

Aims

To characterize nausea with lubiprostone using pooled results from clinical studies in patients with CIC, OIC, or IBS-C.

Methods

Data from three 3- and 4-week placebo-controlled studies and three long-term open-label studies were pooled for the CIC analysis. The OIC and IBS-C analyses each used pooled data from three 12-week placebo-controlled studies and one 36-week open-label extension study.

Results

The populations included t

SUBMITTER: Cryer B 

PROVIDER: S-EPMC5694526 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature